Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

DIRECTOR DEALINGS: Renalytix AI CEO sells USD2 million in shares

25th May 2021 15:50

(Alliance News) - The following is a round-up of share dealings by London-listed company directors and managers announced on Tuesday and not separately reported by Alliance News:

----------

RSA Insurance Group PLC - London-based general insurer - Ken Norgrove, chief executive officer for Scandinavia, buys 5,301 shares at GBP6.84, worth GBP36,269, on Friday last week as part of a trading plan agreed back in 2019. On Tuesday, the High Court of Justice in England & Wales sanctioned the scheme by which RSA will be acquired and split up by Intact Financial Corp and Tryg SA. The effective date for the acquisition will be Tuesday next week, and RSA shares are expected to be delisted from the London Main Market on Wednesday next week. The deal, agreed in mid-November last year, values RSA at GBP7.2 billion.

----------

Renalytix AI PLC - Cardiff, Wales-based clinical diagnostics for kidney disease - CEO James McCullough sells 10,462 American Depositary Shares, each representing two shares, at USD32.25 and USD32.27, worth USD337,439, on Friday last week and Monday. McCullough had sold USD1.7 million in shares on Thursday. He now is interested in 2.7 million shares, a 3.8% stake.

----------

TBC Bank Group PLC - Tbilisi, Georgia-headquartered lender - Nikoloz Kurdiani, deputy CEO of JSC TBC Bank, sells 5,000 shares at average GBP11.16, worth GBP55,800, on Monday. Kurdiani sold 8,163 shares last week. Nino Masurashvili, also deputy CEO of JSC TBC Bank, sells 15,000 shares at average GBP10.64, worth GBP159,539, on Thursday and Friday last week. Earlier last week, Masurashvili had sold 10,000 shares.

----------

Diversified Energy Co PLC - Birmingham, Alabama-based energy producer and distributor - Senior Independent Non-Executive Director David Turner buys 124,500 shares at GBP1.14, worth GBP141,320, on Monday. Now has 371,500 shares.

----------

Oxford BioMedica PLC - Oxford, England-based gene and cell therapy - Chief Operations Officer Nicholas Page exercises options over 4,119 shares and sells all of them at 1,128p, worth GBP46,462, on Friday. Page continues to hold options over 89,436 shares.

----------

By Tom Waite; [email protected]

Copyright 2021 Alliance News Limited. All Rights Reserved.

FTSE 100 Latest
Value8,144.13
Change0.00